Concerns Regarding Phase 1b Clinical Trial of Atezolizumab Plus nab-Paclitaxel for Metastatic Breast Cancer

To the Editor In the study by Adams et al,1 the results of a phase 1b clinical trial with a 2-year-follow-up revealed that atezolizumab plus nab-paclitaxel was clinically safe and tolerable in patients with metastatic triple-negative breast cancer. However, we have some concerns.